- Headquarters
- Zurich
- Founded
- 2022
- Business Model
- B2B
- Website
- adularia.ch
About
Adularia is a Zurich-based preclinical biotech spin-off from the University of Zurich, founded in 2022 and formerly known as Recolony, developing precision cancer immunotherapies. The company's research uncovered a novel molecular mechanism rooted in the symbiotic interplay between gut microbes and the immune system, which it is leveraging to design tumor-targeted small-molecule immunotherapies. Adularia combines microbiome-based target identification, AI-powered molecule design, and multi-omics guided patient selection to develop first-in-class treatments that enhance the body's natural immune response against cancer.
Summary
Adularia is a Biotech company based in Zurich, Switzerland, founded in 2022.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
Novel bicyclic peptides and drug conjugates for cancer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/adularia"><img src="https://indexed.vc/api/badge/company/adularia" alt="Adularia on Indexed.vc" width="260" height="76" /></a>